Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Freshworks Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Freshworks Inc trades at $10.26 (market cap $2.87B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FRSH | |
|---|---|---|
Market Cap | $4.49B | $2.87B |
Sector | Health | Technology |
52-Week High | $28.06 | $15.36 |
52-Week Low | $20.06 | $6.88 |
Enterprise Value | $3.69B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Freshworks (FRSH) trades at $10.38, up 0.39% with a bullish technical signal. The company shows strong revenue growth from $498M in 2022 to $839M in 2025, achieving profitability with a net margin of 20.69%. Recent news highlights AI-driven service platform adoption, including Vanquis selecting Freshservice. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook is positive due to accelerating revenue growth and expanding margins, though high EV/EBITDA of 48.15 suggests premium valuation. Risks include competitive pressures in SaaS and execution challenges in sustaining growth. Upside potential exists if the company maintains its earnings beat trend and capitalizes on AI integration demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
